Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure

NC Lai, DM Roth, MH Gao, T Tang, N Dalton, YY Lai… - Circulation, 2004 - Am Heart Assoc
NC Lai, DM Roth, MH Gao, T Tang, N Dalton, YY Lai, M Spellman, P Clopton, HK Hammond
Circulation, 2004Am Heart Assoc
Background—We tested the hypothesis that intracoronary delivery of an adenovirus
encoding adenylyl cyclase type VI (Ad. ACVI) would be associated with increased left
ventricular (LV) function in pigs with congestive heart failure. Methods and Results—Pigs
(52±6 kg; n= 16) underwent placement of pacemakers, LV pressure transducers, and left
atrial and aortic catheters. Physiological and echocardiographic studies were obtained from
conscious animals 13 days later, and pacing was initiated (220 bpm). Seven days later …
Background— We tested the hypothesis that intracoronary delivery of an adenovirus encoding adenylyl cyclase type VI (Ad.ACVI) would be associated with increased left ventricular (LV) function in pigs with congestive heart failure.
Methods and Results— Pigs (52±6 kg; n=16) underwent placement of pacemakers, LV pressure transducers, and left atrial and aortic catheters. Physiological and echocardiographic studies were obtained from conscious animals 13 days later, and pacing was initiated (220 bpm). Seven days later, measures of LV function were reduced, documenting severe LV dysfunction and dilation. Pigs then received intracoronary Ad.ACVI (1.4×1012 vp; n=7) or saline (PBS; n=9) (randomized, blinded), with concomitant infusion of nitroprusside (50 μg/min, 6.4 minutes) to increase gene transfer. Pacing was continued for 14 days, and final studies were obtained. The a priori key end point was change in LV dP/dt during isoproterenol infusion (pre-Ad.ACVI value minus value after 21 days of pacing). Pigs receiving Ad.ACVI showed a smaller decrease in both LV +dP/dt (P=0.0014) and LV −dP/dt (P=0.0008). Serial echocardiography showed that Ad.ACVI treatment was associated with increased LV function and reduced LV dilation and that end-systolic wall stress was reduced. AC-stimulated cAMP production was increased 1.7-fold in LV samples from Ad.ACVI-treated pigs (P=0.006), and B-type natriuretic peptide was reduced (0.035). Gene transfer was confirmed by polymerase chain reaction.
Conclusions— ACVI gene transfer increases LV function and attenuates deleterious LV remodeling in congestive heart failure.
Am Heart Assoc